---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-056678"
form_type: "8-K"
ticker: "SILO"
cik: "0001514183"
company_name: "Silo Pharma, Inc."
filed_at: "2024-06-27T23:59:59+00:00"
generated_at: "2026-06-01T00:59:14.522764+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Silo Pharma amends license milestones with University of Maryland, Baltimore

## Summary
- Fourth Amendment replaces Schedule C diligence milestones under the Master License Agreement.
- New milestones include completing in vitro peptide binding by March 2025 and preclinical studies by September 2025.
- IND filing for a Licensed Product due by February 2028; first commercial sale by February 2034.
- All other terms, including royalty rate and payment obligations, remain unchanged.

## SEC filing metadata
- accession: 0001213900-24-056678
- form_type: 8-K
- ticker: SILO
- cik: 0001514183
- company_name: Silo Pharma, Inc.
- filed_at: 2024-06-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1514183/000121390024056678/0001213900-24-056678-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1514183/000121390024056678/ea0208662-8k_silo.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-056678
- JSON: https://secwatch.observer/filing/0001213900-24-056678.json
- Plain text: https://secwatch.observer/filing/0001213900-24-056678.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.